Niagen Bioscience
NAGE
83 hedge funds and large institutions have $75.9M invested in Niagen Bioscience in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 15 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
20% more call options, than puts
Call options by funds: $185K | Put options by funds: $154K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.45% less ownership
Funds ownership: 30.08% → 29.64% (-0.45%)
3% less funds holding
Funds holding: 86 → 83 (-3)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
41% less capital invested
Capital invested by funds: $129M → $75.9M (-$53.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$625K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$606K |
| 3 |
Two Sigma Investments
New York
|
+$504K |
| 4 |
Goldman Sachs
New York
|
+$426K |
| 5 |
Millennium Management
New York
|
+$393K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$4.27M |
| 2 |
Barclays
London,
United Kingdom
|
-$974K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$557K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$489K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$304K |
NAGE Hedge Fund Activity: Q4 2021 in Review
83 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2021, worth a combined $75.9M — down 41% from $129M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of NAGE and 13 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 29 added.
The largest buyer was Tieton Capital Management, adding an estimated $625K. The largest seller was Uniplan Investment Counsel, exiting entirely with an estimated $4.27M sold.
- 83 institutional investors held Niagen Bioscience (NAGE) as of Q4 2021, down from 86 in Q3 2021.
- Funds reported $75.9M of Niagen Bioscience stock for Q4 2021, down 41% quarter-over-quarter.
- 13 funds opened new Niagen Bioscience positions in Q4 2021 and 15 closed out, a net change of -2 holders.
- The largest Niagen Bioscience buyer in Q4 2021 was Tieton Capital Management, an estimated $625K added.
- The largest Niagen Bioscience seller in Q4 2021 was Uniplan Investment Counsel, an estimated $4.27M sold.
Based on aggregated 13F filings for Q4 2021.